The #DisruptBTKII# conversation continues with new 2-year results. ⚡ Hear the reactions from Drs. Venita Chandra, Kyle Reynolds (@KReyMD), and Chris Papryzcki (@CincyVascSurg) on the 24-month outcomes presented as a Late Breaker at #VIVA26#, including sustained clinical benefits, significant quality-of-life gains, low reintervention rates, and ongoing limb preservation in patients with calcified BTK disease. Learn more: @VIVAPhysicians #PeripheralIVL# US Rx only. Safety Info: Product availability may vary by country.